Due to its abundant patient population and diseases not being limited by borders, the Asia-Pacific (APAC) region, home to more than half of the world’s population, has emerged as a hub for clinical trials in the global economy. Our previous white paper, “Asia Pacific as a Clinical Trials Powerhouse,” published in 2022, extensively examined the APAC clinical trials landscape from 2012 to 2021. The observed growth in clinical trial activities during this period was remarkable, highlighting the APAC region’s increased significance in global research. At that time, we therefore anticipated APAC’s continued expansion and influence in global clinical activities. 

The evolving demands brought about by the COVID-19 pandemic and the subsequent reopening phases are set to transform not only the global clinical trial environment, but also the landscape trajectory of clinical trials within the APAC region. This year, our analysis delves into the APAC clinical trial landscape from 2019 to 2023. Our latest investigation examines the five fundamental aspects — when, where, who, what, and why — of the APAC clinical trials landscape, drawing insights from Citeline’s Trialtrove platform for clinical trial intelligence. 

For the full report, please download the PDF version at the top of this page.